AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21704968 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-eight closure (group A)
Number of subjects: 150
Study 21704968 — intervention group
Group type: COMPARATOR
Intervention: Sternal weave closure (group B)
Number of subjects: 150
Study 19652565 — intervention group
Group type: EXPERIMENTAL
Intervention: PLL removed
Number of subjects: 58
Study 19652565 — intervention group
Group type: COMPARATOR
Intervention: PLL preserved
Number of subjects: 58
Study 17607002 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke
Number of subjects: 0
Study 17607002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone
Number of subjects: 0
Study 17607002 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 0
Study 15510795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 72
Study 15510795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 72
Study 11555566 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin plus standard CF care
Number of subjects: 0
Study 11555566 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard CF care
Number of subjects: 0
Study 9626184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (32 degrees C)
Number of subjects: 39
Study 9626184 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 39
Study 7884789 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4.5 +/- 2.9 mg/day)
Number of subjects: 44
Study 7884789 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (12.5 +/- 6.5 mg/day)
Number of subjects: 44
Study 7884789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 44
Study 7884789 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 44
Study 2905254 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg twice a day for 7 days
Number of subjects: 0
Study 2905254 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg daily
Number of subjects: 0
Study 2905254 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg daily
Number of subjects: 0
Study 2905254 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31847705 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional faces during response compatible trials (low conflict)
Number of subjects: 0
Study 31847705 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional faces during response incompatible trials (high conflict)
Number of subjects: 0
Study 31847705 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized conflict and emotion conditions across Experiments 2, 3, and 4
Number of subjects: 0
Study 31847705 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictability of compatibility and emotion
Number of subjects: 0
Study 31472811 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based multifaceted intervention including automated identification of patients at increased risk for CI-AKI, point-of-care information on safe contrast volume targets, personalized recommendations for hemodynamic optimization of intravenous fluids, and follow-up information for patients at risk.
Number of subjects: 31
Study 31472811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 31
Study 28887511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin level as a prognostic factor
Number of subjects: 192
Study 28887511 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram including hemoglobin
Number of subjects: 192
Study 28887511 — intervention group
Group type: EXPERIMENTAL
Intervention: C-index of the model
Number of subjects: 192
Study 28887511 — intervention group
Group type: EXPERIMENTAL
Intervention: Random survival forest (RSF) classifier
Number of subjects: 192
Study 25994142 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KP)
Number of subjects: 0
Study 25994142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25994142 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KP) in high-BAT group
Number of subjects: 0
Study 25994142 — intervention group
Group type: COMPARATOR
Intervention: Placebo in high-BAT group
Number of subjects: 0
Study 25994142 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaempferia parviflora extract (KP) in low-BAT group
Number of subjects: 0
Study 25994142 — intervention group
Group type: COMPARATOR
Intervention: Placebo in low-BAT group
Number of subjects: 0
Study 23449352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential transarterial chemoembolisation (sTACE) with cisplatin 50 mg administered intrarterially 4‐6 hours before PVA embolisation, repeated 3-weekly for up to three treatments
Number of subjects: 86
Study 23449352 — intervention group
Group type: COMPARATOR
Intervention: Transarterial embolisation (TAE) with polyvinyl alcohol (PVA) particles alone, repeated 3-weekly for up to three treatments
Number of subjects: 86
Study 21053841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively stimulating activities
Number of subjects: 16
Study 21053841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 19372355 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine perineural infusion (n = 15)
Number of subjects: 32
Study 19372355 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (n = 15)
Number of subjects: 32
Study 19372355 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine perineural infusion
Number of subjects: 32
Study 17074485 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (n=94)
Number of subjects: 220
Study 17074485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness group (n=60)
Number of subjects: 220
Study 17074485 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=66)
Number of subjects: 220
Study 15131791 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 40,000 U subcutaneously, once weekly
Number of subjects: 185
Study 15131791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 15131791 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 185
Study 11465928 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP
Number of subjects: 387
Study 11465928 — intervention group
Group type: COMPARATOR
Intervention: Non-BiPAP
Number of subjects: 387
Study 9715439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular irrigation fluid with 1:1,000,000 adrenaline
Number of subjects: 42
Study 9715439 — intervention group
Group type: COMPARATOR
Intervention: Control group (intraocular irrigation fluid without adrenaline)
Number of subjects: 42
Study 9715439 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (intraocular irrigation fluid with adrenaline)
Number of subjects: 42
Study 15374309 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group programme (8 sessions of 2 hours each)
Number of subjects: 41
Study 15374309 — intervention group
Group type: COMPARATOR
Intervention: Control group (informal monthly meetings of the Alzheimer's Society)
Number of subjects: 41
Study 2646896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hydrochlorothiazide (HCTZ), 25 mg twice daily, with dose reduction
Number of subjects: 606
Study 2646896 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose hydrochlorothiazide (HCTZ), 50 mg twice daily, with dose reduction
Number of subjects: 606
Study 2646896 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose HCTZ plus a low or high dose of a step II drug (propranolol, clonidine or reserpine), with dose reduction
Number of subjects: 606
Study 2646896 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving continued treatment
Number of subjects: 606
Study 30545702 — intervention group
Group type: EXPERIMENTAL
Intervention: BRILMA block (interfascial blockade of the lateral cutaneous branches of the intercostal nerves)
Number of subjects: 0
Study 30545702 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative analgesia (paracetamol and dexketoprofen)
Number of subjects: 0
Study 30545702 — intervention group
Group type: EXPERIMENTAL
Intervention: BRILMA block
Number of subjects: 0
Study 30545702 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative analgesia
Number of subjects: 0
Study 28805175 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education and monitoring programme
Number of subjects: 238
Study 28805175 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 238
Study 27435514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (250 mg bolus followed by 500 mg infusion at 20 mL/hour)
Number of subjects: 108
Study 27435514 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 108
Study 27435514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 108
Study 27435514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate and normal saline
Number of subjects: 108
Study 24848854 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐paced DVD
Number of subjects: 102
Study 24848854 — intervention group
Group type: EXPERIMENTAL
Intervention: Live expert‐led educational seminar
Number of subjects: 102
Study 24848854 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study 22200381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrical splint/general stretch
Number of subjects: 124
Study 22200381 — intervention group
Group type: EXPERIMENTAL
Intervention: General splint/lumbrical stretch
Number of subjects: 124
Study 22200381 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 124
Study 19756505 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP 0.033 IU/min
Number of subjects: 50
Study 19756505 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP 0.067 IU/min
Number of subjects: 50
Study 19756505 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 50
Study 17951487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (48,000 IU)
Number of subjects: 11619
Study 17951487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11619
Study 16336888 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous photocoagulation with an 810 nm diode laser
Number of subjects: 20
Study 16336888 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping operation
Number of subjects: 20
Study 11880827 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam fast-dissolving dosage form (2 tablets sublingually 1 to 3 hours before surgery, repeated with 2 tablets after 24 hours, then 1 tablet after 48 hours)
Number of subjects: 50
Study 11880827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets administered sublingually 1 to 3 hours before surgery, repeated with 2 tablets after 24 hours, then 1 tablet after 48 hours)
Number of subjects: 50
Study 10592453 — intervention group
Group type: EXPERIMENTAL
Intervention: Norditropin((R)) SimpleXx(TM)
Number of subjects: 67
Study 10592453 — intervention group
Group type: EXPERIMENTAL
Intervention: PenMate(TM)
Number of subjects: 67
Study 10592453 — intervention group
Group type: EXPERIMENTAL
Intervention: Norditropin((R)) SimpleXx(TM) and the auto-insertion device
Number of subjects: 67
Study 7589042 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. 0.2 mg moxonidine
Number of subjects: 10
Study 7589042 — intervention group
Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 10
Study 2083492 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational day-care plus family support
Number of subjects: 65
Study 2083492 — intervention group
Group type: EXPERIMENTAL
Intervention: Family education (less intensive intervention)
Number of subjects: 65
Study 2083492 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 372593 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 202
Study 372593 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 202
Study 30804667 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week swallowing treatment protocol including effortful swallows, Mendelsohn maneuvers, tongue‐hold swallows, supraglottic swallows, Shaker exercises and effortful pitch glides, conducted once per week with additional daily home practice.
Number of subjects: 9
Study 30804667 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week swallowing treatment protocol
Number of subjects: 9
Study 28011290 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized content knowledge workshop (50-min BLS workshop)
Number of subjects: 203
Study 28011290 — intervention group
Group type: COMPARATOR
Intervention: Common content knowledge workshop (50-min BLS workshop)
Number of subjects: 203
Study 25796973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension patients (experimental group)
Number of subjects: 300
Study 25796973 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 300
Study 23815518 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cholesterol‐lowering supplement (NCLS) containing red yeast rice, policosanols and artichoke leaf extracts, given over 16 weeks
Number of subjects: 100
Study 23815518 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cholesterol‐lowering supplement (NCLS)
Number of subjects: 100
Study 23815518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21837954 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser vaporesection of the prostate (TmLRP)
Number of subjects: 118
Study 21837954 — intervention group
Group type: COMPARATOR
Intervention: Greenlight photoselective vaporization prostatectomy (PVP)
Number of subjects: 118
Study 21837954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PVP and TmLRP
Number of subjects: 118
Study 19626475 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 ml/kg)
Number of subjects: 27
Study 19626475 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.2 ml/kg)
Number of subjects: 27
Study 19626475 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 27
Study 19626475 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 27
Study 17908831 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) administered 1 hour before blood collection
Number of subjects: 20
Study 15520759 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (Lactobacillus rhamnosus 19070‐2 and L reuteri DSM 12246) for 6 weeks
Number of subjects: 41
Study 15520759 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (Lactobacillus rhamnosus 19070‐2 and L reuteri DSM 12246)
Number of subjects: 41
Study 15520759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence and density in chronic hepatitis specimens
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence and density in cirrhosis specimens
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence and density in hepatocellular carcinoma specimens
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence in hepatoma cells
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor presence in nonmalignant hepatocytes adjacent to hepatocellular carcinoma
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical association between density of hepatocyte growth factor and histological activity index in chronic hepatitis
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical association between density of hepatocyte growth factor and grade of hepatocellular carcinoma
Number of subjects: 90
Study 11264569 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection of hepatocyte growth factor
Number of subjects: 90
Study 9343029 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 5
Study 7839785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms.kg‐1 mixed with 15 mg 0.5% bupivacaine
Number of subjects: 40
Study 7839785 — intervention group
Group type: COMPARATOR
Intervention: Saline mixed with 15 mg 0.5% bupivacaine
Number of subjects: 40
Study 3810831 — intervention group
Group type: EXPERIMENTAL
Intervention: carbonyl iron, 600 mg, three times daily for 1 week
Number of subjects: 75
Study 3810831 — intervention group
Group type: EXPERIMENTAL
Intervention: ferrous sulfate, 300 mg (60 mg Fe++), three times daily for 1 week
Number of subjects: 75
Study 3810831 — intervention group
Group type: COMPARATOR
Intervention: placebo, three times daily for 1 week
Number of subjects: 75
Study 29915059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-level data
Number of subjects: 94
Study 29915059 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level data
Number of subjects: 94
Study 29915059 — intervention group
Group type: COMPARATOR
Intervention: Aggregated statistical estimates
Number of subjects: 94
Study 27296202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 280
Study 27296202 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 280
Study 24731441 — intervention group
Group type: EXPERIMENTAL
Intervention: mCBT (guided Internet-based cognitive behavior therapy)
Number of subjects: 52
Study 24731441 — intervention group
Group type: COMPARATOR
Intervention: mIPT (guided self-help treatment based on interpersonal psychotherapy)
Number of subjects: 52
Study 22094111 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal anticipation
Number of subjects: 29
Study 22094111 — intervention group
Group type: COMPARATOR
Intervention: Control (no meal anticipation)
Number of subjects: 29
Study 15729096 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure intervention through five 1-hour group sessions
Number of subjects: 25
Study 15729096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 11926080 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 193
Study 11926080 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 193
Study 11926080 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine
Number of subjects: 193
Study 11926080 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 193
Study 11926080 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 193
Study 11926080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 193
Study 10396191 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of 5‐isosorbide mononitrate (ISMO)
Number of subjects: 12
Study 10396191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7572685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 885
Study 7572685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study 2381309 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Resistance (CR) training
Number of subjects: 49
Study 2381309 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR) training
Number of subjects: 49
Study 2381309 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 49
Study 7027889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15
Study 7027889 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 7027889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7027889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 15
Study 31376788 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min/day for 4 weeks)
Number of subjects: 12
Study 27786406 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Hodgkin International Prognostic Score (CHIPS)
Number of subjects: 1103
Study 25108626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management intervention (at least one home visit and quarterly telephone calls)
Number of subjects: 329
Study 25108626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management intervention
Number of subjects: 329
Study 23394433 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric calorie label
Number of subjects: 0
Study 23394433 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic calorie label
Number of subjects: 0
Study 23394433 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie labels (general)
Number of subjects: 0
Study 21476205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphygmography
Number of subjects: 135
Study 18269596 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS064D (Sebclair)
Number of subjects: 60
Study 18269596 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study 17003087 — intervention group
Group type: EXPERIMENTAL
Intervention: d3/fl‐GHR genotype in short SGA patients
Number of subjects: 247
Study 17003087 — intervention group
Group type: COMPARATOR
Intervention: d3/d3 genotype in ACPNH
Number of subjects: 247
Study 12631501 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Deprivation and Restriction (Dep/Res)
Number of subjects: 40
Study 12631501 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Deprivation without Restriction (Dep/No Res)
Number of subjects: 40
Study 12631501 — intervention group
Group type: COMPARATOR
Intervention: No Food Deprivation with Restriction (No Dep/Res)
Number of subjects: 40